Drug Discovery World

JUNE 15, 2023

Hosted by DDW and sponsored by DNA Script, ‘Drug discovery and development trends – what will have most impact?’ Roundtable panelists include Commercial Research Scientist, Dr Mark Treherne, CEO of Elevation Oncology, Joe Ferra, and CEO of BioXcel Therapeutics, Vimal Mehta. What can we expect from the cell & gene therapy market?

Development 52

Development Drugs Gene Therapy DNA 52

Drug Discovery World

JUNE 8, 2023

Hosted by DDW and sponsored by DNA Script, ‘Drug discovery and development trends – what will have most impact?’ Roundtable panelists include Commercial Research Scientist Dr Mark Treherne, CEO of Elevation Oncology, Joe Ferra, and CEO of BioXcel Therapeutics, Vimal Mehta. What can we expect from the cell & gene therapy market?

Development 52

Development Drugs Gene Therapy DNA 52

Drug Discovery World

APRIL 8, 2024

In addition to this donation, Pfizer has partnered with the AACR for many years to support impactful research and further the careers of eminent cancer scientists and physicians. The pre-clinical study shows the promise of ISB 2001 trispecific antibody targeting BCMA and CD38 against multiple myeloma, and CD3 on T cells.

In-Vivo 52

In-Vivo In-Vitro Antibody Protein 52

Drug Discovery World

NOVEMBER 8, 2022

Researchers from the University of Missouri analysed the DNA sequences of more 200 strains of monkeypox virus spanning multiple decades, from 1965, when the virus first started spreading, to outbreaks in the early 2000s and again in 2022. . “By

Drugs 52

Drugs DNA Vaccination Vaccine 52

Drug Discovery World

FEBRUARY 28, 2024

Scientists have used CRISPR gene editing to target and rapidly destroy glioblastoma cells in an approach that could apply to other highly mutated cancers. Scientists have used CRISPR gene editing to target and rapidly destroy glioblastoma cells in an approach that could apply to other highly mutated cancers. expressing cancers.

Development 64

Development Research Drugs Antibody 64

Roots Analysis

DECEMBER 12, 2023

Over the years, researchers and scientists have been on the lookout to find effective ways to treat various types of oncological disorders. As a result, innovators came up with the idea of magic bullets, antibody drug conjugates (ADCs). It is comprised of three components, namely antibody, drug and linker. Components of an ADC?

Antibody 40

Antibody Manufacturing Drugs RNA 40

The Pharma Data

APRIL 8, 2021

Leadership in DNA damage response demonstrated in multiple presentations for AZD5305, a next-generation PARP1 selective inhibitor. Data for AZD5305 will demonstrate how the next wave of DNA damage response medicines can build on the success of PARP inhibitors, potentially allowing patients to stay on treatment longer.

DNA 52

DNA Medicine Genome Genomics 52

pharmaphorum

SEPTEMBER 29, 2020

The US drugs regulator has placed the phase 2/3 trial of INO-4800 on partial clinical hold while it seeks answers from the company about the DNA-based vaccine as well as the device used to deliver the shot to patients in the study. An expanded phase 1 trial of the shot is still ongoing and unaffected by the partial hold.

Vaccination 52

Vaccination Vaccine Trials DNA 52

Delveinsight

AUGUST 6, 2020

The Indian company informed that the DNA vaccine was well tolerated in the first stage of the adaptive phase 1/2 trial. ZyCoV-D is designed to introduce DNA that encodes for a viral protein into human cells. Scientists have already isolated many highly potent neutralizing antibodies from patients who recovered from COVID-19.

Allergies 53

Allergies Vaccination Vaccine Gene Therapy 53

pharmaphorum

DECEMBER 21, 2020

Their technology is based on synthetic messenger RNA – short for ribose nucleic acid – which is a short transcript of a longer DNA code. The body produces antibodies against the protein, which neutralise the virus in the event of an infection. They are very good doctors, scientists and entrepreneurs.

Vaccination 111

Vaccination Vaccine Doctors Doctor 111

Drug Discovery World

NOVEMBER 15, 2022

Rapid and accurate DNA synthesis . Conventional DNA synthesis, typically used for making sequences such as primers, employs phosphoramidite chemistry, a method that was developed in the 1980s and is still considered the gold standard for DNA synthesis. .

DNA 98

DNA Drugs Antibody Engineer 98

Drug Discovery World

OCTOBER 16, 2023

Alchemab, on the other hand, has developed a highly differentiated platform which enables the identification of novel drug targets and therapeutics by analysis of patient antibody repertoires, drawing from the expertise in Cambridge to progress the company’s mission to build a broad pipeline of protective therapeutics for hard-to-treat diseases.

Drugs 75

Drugs Life Science Gene Therapy Genome 75

Drug Discovery World

NOVEMBER 9, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Kielczewska will present: ‘Discovery of antibody-based therapeutics to challenging targets: Platform considerations’.

Engineer 52

Engineer Antibody Protein In-Vivo 52

Pharmaceutical Technology

FEBRUARY 3, 2023

With scientists fervently developing mRNA vaccines, nucleic acid therapeutics, and viral vector-based gene therapies, clinicians are set to have a growing number of tools available to treat a wide range of conditions, from infectious diseases to genetic disorders and more. The field of genomic medicine has reached a true turning point.

Genome 244

Genome Genomics Medicine Gene Therapy 244

Drug Discovery World

NOVEMBER 13, 2023

Ahead of protein and antibody engineering conference PEGS Europe 2024 in Lisbon, DDW’s Megan Thomas looks at what to expect from each track of the annual biologics technology meeting. Hiroki Shirai, PhD, Coordinator, RIKEN Center for Computational Science, on: ‘Applying deep learning anomaly detection to antibody structures’.

Protein 59

Protein Antibody Engineer Scientist 59

Drug Discovery World

SEPTEMBER 7, 2022

If all the work scientists do is captured in software, it ought to be easier to analyse. . Many companies have embarked on a digitalisation journey, convinced that their notebook entries, DNA and protein designs, samples used in experiments, and experimental conditions should all be tracked and stored in software.

Scientist 52

Scientist Life Science Antibody Protein 52

Delveinsight

DECEMBER 3, 2020

Roche receives FDA authorization for the quantitative COVID-19 antibody test. Roche has got an authorization from the FDA for a more accurate COVID-19 blood test capable of measuring the levels of specific antibodies, which target the cell-unlocking spike protein of coronavirus. Reversing vision loss by rolling back the ageing clock.

Gene Therapy 52

Gene Therapy Gene Antibody Research 52

Drug Discovery World

JULY 11, 2023

Now, with the growth of publicly available genomics, transcriptomics, and proteomics databases, the ability to quickly carry out large-scale DNA, RNA, and protein screenings, and the availability of massive sets of de-identified patient data, the amount of high-value, analysable data has reached enormous proportions.

Big Data 40

Big Data Development Life Science Drugs 40

Drug Discovery World

NOVEMBER 30, 2023

The company’s goal is to accelerate functional characterisation and shortenoptimisation time in antibody discovery and t-cell workflows. Lightcast is developing a novel, programmable microfluidic platform that allows precise and highly flexible control of individual microdroplets using software-generated light patterns.

Antibody 59

Antibody Protein Engineer In-Vivo 59

Bioengineer

JULY 23, 2021

The LOTIS-2 trial tested the efficacy of Loncastuximab tesirine, an antibody-drug complex that targets CD19 – the same molecule targeted on the lymphoma B-cells by CAR-T therapy. Once internalized, the drug damages the DNA of the lymphoma cells, leading to cell death. MUSC and its affiliates have collective annual budgets of $3.2

Trials 52

Trials Antibody Drugs Clinical Trials 52

pharmaphorum

SEPTEMBER 13, 2022

During this period, Nobel prize-winning German scientist Paul Ehrlich developed his lock-key hypothesis of molecules that specifically bind to cell receptors. Further research led Ehrlich to develop his side-chain theory, that antibodies produced by white blood cells act as receptors on the cell membrane.

Genome Project 98

Genome Project Genome Genomics DNA 98

Drug Discovery World

AUGUST 10, 2022

Next, the advent of antibody treatments in 1997 created the first targeted cancer therapy 2. Later, scientists took advantage of antibodies’ natural tendency to seek out specific antigens and created antibody therapies that guide T cells towards the cells they are supposed to destroy.

Manufacturing 98

Manufacturing Gene Genome Genomics 98

Drug Discovery World

APRIL 25, 2024

Grand View Research states that the market for cell lines is currently bolstered by the fact that the majority of biopharma companies use cell lines to synthesise recombinant monoclonal antibodies and proteins. Bacterial cell lines such as E. coli have their own set of benefits however.

Development 59

Development Protein In-Vivo Life Science 59

Drug Discovery World

JULY 18, 2023

Rolf Turk , Senior Manager, Genomics Medicine at Integrated DNA Technologies, examines how CRISPR is being used to enhance cancer therapies. parvovirus B19, Flaviviridae, Ebola, and Coronaviridae), DNA viruses (e.g., To achieve cell-specific delivery, many systems rely on using cell-specific DNA aptamers (e.g.,

DNA 98

DNA Genome Genomics RNA 98

The Pharma Data

DECEMBER 3, 2020

Significant differences among COVID-19 diagnostic tests are resulting in inaccurate results that sometimes put populations at risk or quarantine people needlessly, contributing to skepticism about pronouncements from scientists and public health authorities. Other techniques are primed to replace it.

RNA 52

RNA Protein DNA Antibody 52

The Pharma Data

JANUARY 21, 2021

The test valuates mitochondrial DNA levels. When mitochondrial DNA, normally found inside cells, in the mitochondria, spills into the bloodstream, it signals that a particular type of violent cell death is occurring. They measured the patients’ mitochondrial DNA levels on the first day of their hospital stays. and William E.

Research 52

Research DNA Hormones Vaccination 52

The Pharma Data

OCTOBER 14, 2020

Potential Development of Human Monoclonal Antibody Therapeutics to SARS-CoV-2. The research is part of an ongoing collaboration between Columbia University and Tonix that focuses on T cell and antibody responses to SARS-CoV-2 (CoV-2), the virus that causes COVID-19. CHATHAM, N.J., Ilya Trakht, Ph.D.,

Vaccination 40

Vaccination Vaccine Development Medicine 40

Drug Discovery World

MAY 11, 2023

In these cases, injection of the viral vector vaccines induced the production of antibodies recognising platelet factor 4 (PF4) found on patients’ platelets 1. These assays require large quantities of high-affinity anti-HCP antibodies and still fail to cover the complete HCP profile.

Production 52

Production Gene Protein Vaccination 52

XTalks

AUGUST 2, 2023

2) Darzalex (daratumumab) Darzalex is a targeted monoclonal antibody that slows or stops the progression of multiple myeloma (a blood cancer) by binding to the CD38 protein on multiple myeloma cells. The monoclonal antibody targets CD20, a protein found on the surface of B lymphocytes (B cells). billion in 2022, a 32.44

Sales 98

Sales Manufacturing FDA Approval Life Science 98

Drug Discovery World

FEBRUARY 27, 2023

Carterra’s LSA antibody discovery and characterisation platform was launched in 2018 to enable automated workflows in single unattended runs. Cellario integrates all devices and software within a laboratory, helping scientists customise and implement technologies to produce data so they can execute their work.

Drugs 52

Drugs Life Science Protein Scientist 52

The Pharma Data

JANUARY 13, 2021

” The Johnson & Johnson vaccine also would be hardier than either of the already approved vaccines because it relies on DNA technology rather than messenger RNA to prompt an immune system response. More than 90% of participants mounted an immune response within a month, and all had levels of neutralizing antibodies by day 57.

Vaccination 40

Vaccination Vaccine Trials Immune Response 40

Drug Discovery World

OCTOBER 17, 2023

The expertise in the field is growing and a talented pool of scientists who have the experience and knowledge to deliver cross-disciplinary data is a niche but growing group. Prior to that, he worked in QIAGEN’s R&D division and was one the first scientists to join Resolve Biosciences. Let’s take CAR T cells as an example.

Gene Expression 52

Gene Expression Drugs Protein Gene 52

Drug Discovery World

OCTOBER 7, 2022

HR : To give some specific examples, going forward, immunotherapy will certainly be a major focus for Cancer Research Horizons, but there are also new emerging areas of science arising from our Cancer Research UK and Grand Challenge network, such as DNA Damage Repair, RNAi and extrachromosomal DNA.

HR 52

HR Research Drugs Development 52

pharmaphorum

JULY 26, 2022

At a basic level, the virus’s protein ‘coat’ and the enzymes it uses to gain control of the host cell’s DNA mutate frequently, making it difficult to target with therapeutics. The reason there has been, as yet, no effective cure for the condition is due to the complexity of the virus and the way in which it is activated within the body.

Gene Therapy 140

Gene Therapy Protein Vaccination Vaccine 140

XTalks

DECEMBER 24, 2020

After being identified in December 2019 in Wuhan, Hubei in China, medical officials and scientists got to work to isolate and identify the novel virus that they observed to be causing a new respiratory illness. Most antibody drugs and vaccines have been developed to target parts of the spike protein. Drug Approvals.

Life Science 111

Life Science Vaccination Vaccine Gene 111

Pharmaceutical Technology

DECEMBER 7, 2022

Lecanemab is an amyloid antibody that targets oligomers and protofibrils of amyloid. In another study (S-1 CTAD 2022), scientists analyses blood plasma levels of p-tau along with other biomarkers using opsitron emission tomography (PET) scans and clinical and cognitive measures in local and international clinical cohorts.

Development 264

Development Drugs Clinical Trials Clinical Trials 264

Pharmaceutical Technology

DECEMBER 7, 2022

Lecanemab is an amyloid antibody that targets oligomers and protofibrils of amyloid. In another study (S-1 CTAD 2022), scientists analyses blood plasma levels of p-tau along with other biomarkers using opsitron emission tomography (PET) scans and clinical and cognitive measures in local and international clinical cohorts.

Development 246

Development Drugs Clinical Trials Clinical Trials 246